Latest news with #NewChemicalEntities
&w=3840&q=100)
Business Standard
02-05-2025
- Business
- Business Standard
Ashish Kacholia portfolio stock surges 10% on strong Q4 performance
Share price of Ami Organics today Share of Ami Organics surged 10 per cent to ₹ 1,243 on the BSE in Friday's intra-day deal, after the company reported healthy operational performance for the quarter ended March 2025 (Q4FY25). In the past two trading days, the stock price of the pharmaceutical company has rallied 14 per cent. It had hit a 52-week high of ₹ 1,321.75 (adjusted to stock split) on February 5, 2025. At 02:31 pm; Ami Organics was trading 6 per cent higher at ₹ 1,196, as compared to 0.15 per cent rise in the BSE Sensex. Stock Split from ₹ 10 to ₹ 5 On April 25, 2025, share price of Ami Organics turned ex-date for stock split. The company had fixed April 25, 2025 as the 'Record Date' for determining entitlement of equity shareholders for the purpose of for split/ sub-division of equity shares of the company, such that 1 equity share having face value of ₹10, divided into 2 equity shares having face value of ₹5 each. The rationale behind the stock split was to enhance liquidity of the equity shares of the company in the stock market and to encourage wider participation of small investors by making equity shares of the company more affordable. Ashish Kacholia holds 1.72 per cent stake in Ami Organics Investor Ashish Kacholia held 704,974 equity shares representing 1.72 per cent stake in Ami Organics at the end of March 2025 quarter, the shareholding pattern data showed. However, Kacholia, reduced his stake in the company by 0.12 percentage points, from 1.84 per cent stake at the end of December 2024 quarter. Q4 operational performance of Ami Organics In January to March 2025 quarter (Q4FY25), Ami Organics reported 144 per cent jump in its consolidated profit after tax (PAT) at ₹ 62.7 crore, against ₹ 25.7 crore in Q4FY24. Revenue from operations grew 37.1 per cent year-on-year (YoY) at ₹ 308.5 crore. Earnings before interest, taxes, depreciation, and amortization (EBITDA) margin expanded to 27.5 per cent from 19.2 per cent in Q4FY24. Looking ahead to FY26, the management anticipates robust growth across all business segments, driving confidence in achieving 25 per cent revenue growth. About Ami Organics Ami Organics is a research and development (R&D) driven manufacturer of speciality chemicals focused towards the development and manufacturing of advanced pharmaceutical intermediates (Pharma Intermediates) for regulated and generic active pharmaceutical ingredients (APIs) and chemicals for New Chemical Entities (NCE), and other specialty chemicals including parabens and paraben formulations, methyl salicylate , semiconductor chemicals, electrolyte additives and niche key starting materials (KSM) for cosmetics, fine chemicals and agrochemical industries. The Pharma Intermediates, find application in certain high-growth therapeutic areas including anti-depressant, anti-cancer, anti-retroviral, anti-Parkinson, and seizure disorder. Ami Organics is the market leader for various key intermediates across the globe and the first company in India outside of China to spearhead the pioneering development of electrolyte additives on a global scale.
Business Standard
02-05-2025
- Business
- Business Standard
Ami Organics jumps after Q4 PAT soars to Rs 627 cr
Ami Organics rallied 7.87% to Rs 1,219.50 after the company's consolidated net profit surged 144.24% to Rs 627.16 crore during the quarter as compared with Rs 256.78 crore in Q4 FY24. Revenue from operations jumped 37.13% year on year to Rs 308.48 crore during the quarter ended 31st March 2025. Profit before tax (PBT) soared 122.66% to Rs 82.83 crore in Q4 FY25 as compared with Rs 37.20 crore in Q4 FY24. EBITDA stood at Rs 85 crore, registering the growth of 96.8% as compared with Rs 432 crore in Q4 FY24. EBITDA margin was at 27.5% in Q4 FY25 as against 19.2% in Q4 FY24. In Q4 FY25, export stood at 74% and domestic business was at 26%. Naresh Patel, executive chairman & managing director, Ami Organics, said, I am delighted to share that FY25 was a transformative year for Ami Organics, as we proudly surpassed Rs 1,000 crore in revenuea remarkable milestone. This achievement reflects the unwavering dedication of our employees and the invaluable support of our stakeholders, including customers, suppliers, shareholders and all other stakeholders. We extend our heartfelt gratitude for their contributions. Looking ahead to FY26, we anticipate robust growth across all business segments, driving our confidence in achieving 25% revenue growth. Meanwhile, the companys board recommended of final dividend of Rs 1.5 per equity share for FY25. Ami Organics headquartered at Surat, is a research and development (R&D) driven manufacturer of speciality chemicals focused towards the development and manufacturing of advanced pharmaceutical intermediates for regulated and generic active pharmaceutical ingredients (APIs) and chemicals for New Chemical Entities (NCE), and other specialty chemicals.
Yahoo
18-04-2025
- Business
- Yahoo
Dipharma Awarded Bronze Medal by Ecovadis for Sustainability
Recognition Underscores Commitment to Sustainable Practices Dipharma awarded Bronze Medal by EcoVadis MILAN, April 18, 2025 (GLOBE NEWSWIRE) -- Dipharma Francis, a global world class Contract Development and Manufacturing Organization (CDMO) and a leading manufacturer of Active Pharmaceutical Ingredients (APIs), New Chemical Entities (NCE), and advanced Intermediates for Generic and Contract Manufacturing markets, is proud to announce that it has once again been awarded a Bronze Medal for its sustainability achievements by EcoVadis, a recognized and independent ratings platform that assesses corporate social responsibility based on international sustainability standards. EcoVadis has rated Dipharma Francis's performance among the top 35% of all organizations surveyed, placing the Company in the 66th percentile. The assessment is based on 21 indicators across four key areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. This recognition reaffirms Dipharma's ongoing commitment to sustainability and its dedication to integrating responsible practices throughout its the past five years, Dipharma Francis has implemented both technical and managerial solutions that led to a 20% reduction in greenhouse gas emissions and has achieved 20% reduction in hazardous waste, exceeding its initial target of 15%. Additionally, the company has tripled the share of hazardous waste directed to recycling or recovery rather than disposal. 'This bronze medal is a testament to our continuous efforts to embed sustainability into our business model - said Marc-Olivier Geinoz, Chairman and Chief Executive Officer of Dipharma Francis S.r.l. - We strive to reduce our environmental footprint, strengthen our ethical governance, and enhance the well-being and safety of our employees, the community, and the patients who use our APIs. This recognition further confirms our commitment not only to delivering high-quality APIs and tailored services, but also to fostering responsible growth.' About the Dipharma Francis group The Dipharma Group is a global CDMO and a leading manufacturer of APIs and Intermediates, with about 600 skilled and highly committed employees, 4 cGMP plants, located in the U.S.A. and Italy, plus sales offices in Italy, the U.S.A. and China. The fully equipped R&D Centers develop innovative chemical processes and crystalline forms for the most prominent pharmaceutical companies worldwide. As a third-generation family-owned company, Dipharma has a long history of stability, commitment, and financial solidity. Dipharma has the right size and variety of scale-up capabilities to act as a global player and manage processes efficiently, while offering flexibility and agility to promptly solve any challenge. Experience you can For more information: Paola Clerici Communication Manager Dipharma Francis S.r.l. A photo accompanying this announcement is available at
